Biogen Statistics
Total Valuation
Biogen has a market cap or net worth of $28.49 billion. The enterprise value is $30.89 billion.
| Market Cap | 28.49B |
| Enterprise Value | 30.89B |
Important Dates
The last earnings date was Friday, February 6, 2026, before market open.
| Earnings Date | Feb 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biogen has 146.76 million shares outstanding. The number of shares has increased by 0.82% in one year.
| Current Share Class | 146.76M |
| Shares Outstanding | 146.76M |
| Shares Change (YoY) | +0.82% |
| Shares Change (QoQ) | -0.27% |
| Owned by Insiders (%) | 0.20% |
| Owned by Institutions (%) | 96.57% |
| Float | 146.26M |
Valuation Ratios
The trailing PE ratio is 22.09 and the forward PE ratio is 12.39. Biogen's PEG ratio is 4.05.
| PE Ratio | 22.09 |
| Forward PE | 12.39 |
| PS Ratio | 2.88 |
| Forward PS | 2.98 |
| PB Ratio | 1.57 |
| P/TBV Ratio | 11.01 |
| P/FCF Ratio | 13.89 |
| P/OCF Ratio | 12.92 |
| PEG Ratio | 4.05 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.57, with an EV/FCF ratio of 15.06.
| EV / Earnings | 23.89 |
| EV / Sales | 3.12 |
| EV / EBITDA | 8.57 |
| EV / EBIT | 10.94 |
| EV / FCF | 15.06 |
Financial Position
The company has a current ratio of 2.68, with a Debt / Equity ratio of 0.36.
| Current Ratio | 2.68 |
| Quick Ratio | 1.70 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | 1.79 |
| Debt / FCF | 3.25 |
| Interest Coverage | 10.56 |
Financial Efficiency
Return on equity (ROE) is 7.39% and return on invested capital (ROIC) is 11.19%.
| Return on Equity (ROE) | 7.39% |
| Return on Assets (ROA) | 6.14% |
| Return on Invested Capital (ROIC) | 11.19% |
| Return on Capital Employed (ROCE) | 10.82% |
| Weighted Average Cost of Capital (WACC) | 4.81% |
| Revenue Per Employee | $1.32M |
| Profits Per Employee | $172,387 |
| Employee Count | 7,500 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 0.90 |
Taxes
In the past 12 months, Biogen has paid $263.60 million in taxes.
| Income Tax | 263.60M |
| Effective Tax Rate | 16.94% |
Stock Price Statistics
The stock price has increased by +41.36% in the last 52 weeks. The beta is 0.16, so Biogen's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | +41.36% |
| 50-Day Moving Average | 179.30 |
| 200-Day Moving Average | 149.98 |
| Relative Strength Index (RSI) | 60.95 |
| Average Volume (20 Days) | 1,504,930 |
Short Selling Information
The latest short interest is 4.69 million, so 3.20% of the outstanding shares have been sold short.
| Short Interest | 4.69M |
| Short Previous Month | 4.68M |
| Short % of Shares Out | 3.20% |
| Short % of Float | 3.21% |
| Short Ratio (days to cover) | 3.15 |
Income Statement
In the last 12 months, Biogen had revenue of $9.89 billion and earned $1.29 billion in profits. Earnings per share was $8.79.
| Revenue | 9.89B |
| Gross Profit | 7.81B |
| Operating Income | 2.82B |
| Pretax Income | 1.56B |
| Net Income | 1.29B |
| EBITDA | 3.60B |
| EBIT | 2.82B |
| Earnings Per Share (EPS) | $8.79 |
Balance Sheet
The company has $3.82 billion in cash and $6.66 billion in debt, with a net cash position of -$2.41 billion or -$16.42 per share.
| Cash & Cash Equivalents | 3.82B |
| Total Debt | 6.66B |
| Net Cash | -2.41B |
| Net Cash Per Share | -$16.42 |
| Equity (Book Value) | 18.26B |
| Book Value Per Share | 124.37 |
| Working Capital | 5.62B |
Cash Flow
In the last 12 months, operating cash flow was $2.20 billion and capital expenditures -$153.80 million, giving a free cash flow of $2.05 billion.
| Operating Cash Flow | 2.20B |
| Capital Expenditures | -153.80M |
| Free Cash Flow | 2.05B |
| FCF Per Share | $13.97 |
Margins
Gross margin is 78.95%, with operating and profit margins of 28.55% and 13.07%.
| Gross Margin | 78.95% |
| Operating Margin | 28.55% |
| Pretax Margin | 15.74% |
| Profit Margin | 13.07% |
| EBITDA Margin | 36.44% |
| EBIT Margin | 28.55% |
| FCF Margin | 20.73% |
Dividends & Yields
Biogen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.82% |
| Shareholder Yield | -0.82% |
| Earnings Yield | 4.54% |
| FCF Yield | 7.20% |
Analyst Forecast
The average price target for Biogen is $195.13, which is 0.52% higher than the current price. The consensus rating is "Buy".
| Price Target | $195.13 |
| Price Target Difference | 0.52% |
| Analyst Consensus | Buy |
| Analyst Count | 26 |
| Revenue Growth Forecast (5Y) | -0.16% |
| EPS Growth Forecast (5Y) | 15.67% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on January 18, 2001. It was a forward split with a ratio of 3:1.
| Last Split Date | Jan 18, 2001 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Biogen has an Altman Z-Score of 2.97 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.97 |
| Piotroski F-Score | 6 |